Effect of AI Monitoring Blind Spots of EGD on the Inspection Time and Lesion Dection Rate

Effect of Artificial Intelligence Monitoring Blind Spots of EGD on the Inspection Time and Dection Rate of Neoplastic Lesions

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05832411

Enrollment

1672

Registered

2023-04-27

Start date

2023-07-01

Completion date

2024-08-31

Last updated

2023-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Upper Gastrointestinal Symptoms

Keywords

Esophagogastroduodenoscopy, Artificial intelligence, Blind spot

Brief summary

The goal of this clinic trial is to learn about the effect of AI monitoring blind spots on the inspection time to EGD. Patients are randomly assigned to undergo an EGD with or without the assistance of AI. In the AI group, except for the original videos, there is additional information presented to endoscopists:(1)the virtual stomach model monitoring;(2)time;(3)scoring. Researchers will compare intervention group to see if it have a shorter inspection time compared with the control group.

Detailed description

The goal of this clinic trial is to evaluate the effect of real-time artificial intelligence for monitoring blind spots on the inspection time of EGD. Patients are randomly assigned to undergo an EGD with or without the assistance of AI. In the AI group, except for the original videos, there is additional information presented to endoscopists:(1)the virtual stomach model monitoring;(2)time;(3)scoring. Researchers will compare intervention group to see if it have a shorter inspection time in the case of non-inferior detection rate of gastric neoplastic lesions.

Interventions

DEVICEEndoangle

there is additional information presented to endoscopists:（1）the virtual stomach model monitoring；（2）time;（3）scoring.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

OTHER

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

1. patients aged 18 years or older 2. patients able to give informed consent 3. American Society of Anesthesiology risk class 1,2 or 3

Exclusion criteria

1. patients with absolute contraindications to EGD examination 2. patients with a history of previous gastrectomy 3. patients with a serious underlying disease 4. pregnant patients 5. researchers believe that the patient is not suitable to participate in the trial

Design outcomes

Primary

Measure	Time frame	Description
Dection rate of neoplastic lesions	Through study completion, an average of 1 year	Proportion of patients with neoplastic lesions among all patients undergoing esophagogastroduodenoscopy.

Secondary

Measure	Time frame	Description
Inspection time	20min	It is the time from intubation to extubation of the patient without biopsy.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026